Sex differences in HPV immunity among adults without cancer

Melina J. Windon, Tim Waterboer, Alexander Tell Hillel, Wade W Chien, Simon R Best, Charles Matthew Stewart, Lee M Akst, Tanya Troy, Noemi Bender, Brett Miles, William R. Ryan, Rajarsi Mandal, Karen Pitman, David W Eisele, Carole Fakhry, Gypsyamber D'Souza

Research output: Contribution to journalArticle

Abstract

The incidence of human papillomavirus (HPV)-associated head and neck cancers is rising, particularly among men. Whether observed epidemiological differences in sex are explained by differences in sexual exposure and/or by immune response is unclear. In this cross-sectional, multi-institutional study, seroprevalence of antibodies to HPV L1 capsid antigen was compared by patient characteristics among 374 adult patients without cancer. A significantly higher seroprevalence was observed among women compared with men for HPV16 (OR = 2.96, 95% CI = 1.21–7.21) and HPV18 (OR = 2.84, 95% CI = 1.06–7.60) L1 antibodies. This difference persisted for HPV16 after controlling for lifetime and recent sexual behavior. After controlling for sex, HPV16 and HPV18 L1 seroprevalence was also significantly associated with higher number of lifetime (HPV16 OR = 1.05, 95% CI = 1.01–1.08; HPV18 OR = 1.04, 95% CI = 1.01–1.08) and recent (HPV16 OR = 1.54, 95% CI = 1.15–2.07; HPV18 OR = 1.40, 95% CI = 1.07–1.82) oral but not vaginal sexual partners. These findings potentially suggest a more robust immune response to HPV16/18 among women compared with men that may not be explained by differences in number of sexual partners, and thereby presumably HPV exposure. The independent association of HPV16/18 L1 seroprevalence with higher number of oral sexual partners suggests a possible role for site of mucosal exposure in the HPV immune response.

Original languageEnglish (US)
JournalHuman Vaccines and Immunotherapeutics
DOIs
StatePublished - Jan 1 2019

Fingerprint

Seroepidemiologic Studies
Sex Characteristics
Sexual Partners
Immunity
Neoplasms
Leukocyte L1 Antigen Complex
Antibodies
Capsid
Head and Neck Neoplasms
Sexual Behavior
Incidence

Keywords

  • head and neck neoplasms
  • Human papillomavirus
  • seroepidemiologic studies
  • sexual partners

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology

Cite this

@article{30c97ed1fe024df293b02791d22b9d74,
title = "Sex differences in HPV immunity among adults without cancer",
abstract = "The incidence of human papillomavirus (HPV)-associated head and neck cancers is rising, particularly among men. Whether observed epidemiological differences in sex are explained by differences in sexual exposure and/or by immune response is unclear. In this cross-sectional, multi-institutional study, seroprevalence of antibodies to HPV L1 capsid antigen was compared by patient characteristics among 374 adult patients without cancer. A significantly higher seroprevalence was observed among women compared with men for HPV16 (OR = 2.96, 95{\%} CI = 1.21–7.21) and HPV18 (OR = 2.84, 95{\%} CI = 1.06–7.60) L1 antibodies. This difference persisted for HPV16 after controlling for lifetime and recent sexual behavior. After controlling for sex, HPV16 and HPV18 L1 seroprevalence was also significantly associated with higher number of lifetime (HPV16 OR = 1.05, 95{\%} CI = 1.01–1.08; HPV18 OR = 1.04, 95{\%} CI = 1.01–1.08) and recent (HPV16 OR = 1.54, 95{\%} CI = 1.15–2.07; HPV18 OR = 1.40, 95{\%} CI = 1.07–1.82) oral but not vaginal sexual partners. These findings potentially suggest a more robust immune response to HPV16/18 among women compared with men that may not be explained by differences in number of sexual partners, and thereby presumably HPV exposure. The independent association of HPV16/18 L1 seroprevalence with higher number of oral sexual partners suggests a possible role for site of mucosal exposure in the HPV immune response.",
keywords = "head and neck neoplasms, Human papillomavirus, seroepidemiologic studies, sexual partners",
author = "Windon, {Melina J.} and Tim Waterboer and Hillel, {Alexander Tell} and Chien, {Wade W} and Best, {Simon R} and Stewart, {Charles Matthew} and Akst, {Lee M} and Tanya Troy and Noemi Bender and Brett Miles and Ryan, {William R.} and Rajarsi Mandal and Karen Pitman and Eisele, {David W} and Carole Fakhry and Gypsyamber D'Souza",
year = "2019",
month = "1",
day = "1",
doi = "10.1080/21645515.2019.1568157",
language = "English (US)",
journal = "Human Vaccines and Immunotherapeutics",
issn = "2164-5515",
publisher = "Landes Bioscience",

}

TY - JOUR

T1 - Sex differences in HPV immunity among adults without cancer

AU - Windon, Melina J.

AU - Waterboer, Tim

AU - Hillel, Alexander Tell

AU - Chien, Wade W

AU - Best, Simon R

AU - Stewart, Charles Matthew

AU - Akst, Lee M

AU - Troy, Tanya

AU - Bender, Noemi

AU - Miles, Brett

AU - Ryan, William R.

AU - Mandal, Rajarsi

AU - Pitman, Karen

AU - Eisele, David W

AU - Fakhry, Carole

AU - D'Souza, Gypsyamber

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The incidence of human papillomavirus (HPV)-associated head and neck cancers is rising, particularly among men. Whether observed epidemiological differences in sex are explained by differences in sexual exposure and/or by immune response is unclear. In this cross-sectional, multi-institutional study, seroprevalence of antibodies to HPV L1 capsid antigen was compared by patient characteristics among 374 adult patients without cancer. A significantly higher seroprevalence was observed among women compared with men for HPV16 (OR = 2.96, 95% CI = 1.21–7.21) and HPV18 (OR = 2.84, 95% CI = 1.06–7.60) L1 antibodies. This difference persisted for HPV16 after controlling for lifetime and recent sexual behavior. After controlling for sex, HPV16 and HPV18 L1 seroprevalence was also significantly associated with higher number of lifetime (HPV16 OR = 1.05, 95% CI = 1.01–1.08; HPV18 OR = 1.04, 95% CI = 1.01–1.08) and recent (HPV16 OR = 1.54, 95% CI = 1.15–2.07; HPV18 OR = 1.40, 95% CI = 1.07–1.82) oral but not vaginal sexual partners. These findings potentially suggest a more robust immune response to HPV16/18 among women compared with men that may not be explained by differences in number of sexual partners, and thereby presumably HPV exposure. The independent association of HPV16/18 L1 seroprevalence with higher number of oral sexual partners suggests a possible role for site of mucosal exposure in the HPV immune response.

AB - The incidence of human papillomavirus (HPV)-associated head and neck cancers is rising, particularly among men. Whether observed epidemiological differences in sex are explained by differences in sexual exposure and/or by immune response is unclear. In this cross-sectional, multi-institutional study, seroprevalence of antibodies to HPV L1 capsid antigen was compared by patient characteristics among 374 adult patients without cancer. A significantly higher seroprevalence was observed among women compared with men for HPV16 (OR = 2.96, 95% CI = 1.21–7.21) and HPV18 (OR = 2.84, 95% CI = 1.06–7.60) L1 antibodies. This difference persisted for HPV16 after controlling for lifetime and recent sexual behavior. After controlling for sex, HPV16 and HPV18 L1 seroprevalence was also significantly associated with higher number of lifetime (HPV16 OR = 1.05, 95% CI = 1.01–1.08; HPV18 OR = 1.04, 95% CI = 1.01–1.08) and recent (HPV16 OR = 1.54, 95% CI = 1.15–2.07; HPV18 OR = 1.40, 95% CI = 1.07–1.82) oral but not vaginal sexual partners. These findings potentially suggest a more robust immune response to HPV16/18 among women compared with men that may not be explained by differences in number of sexual partners, and thereby presumably HPV exposure. The independent association of HPV16/18 L1 seroprevalence with higher number of oral sexual partners suggests a possible role for site of mucosal exposure in the HPV immune response.

KW - head and neck neoplasms

KW - Human papillomavirus

KW - seroepidemiologic studies

KW - sexual partners

UR - http://www.scopus.com/inward/record.url?scp=85063080007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063080007&partnerID=8YFLogxK

U2 - 10.1080/21645515.2019.1568157

DO - 10.1080/21645515.2019.1568157

M3 - Article

JO - Human Vaccines and Immunotherapeutics

JF - Human Vaccines and Immunotherapeutics

SN - 2164-5515

ER -